Effects of low-dose topiramate on language function in children with migraine

Seung-A Han, MD1, Eu Jeen Yang, MD2, Younghwa Kong, MD1, Chan-Uhng Jo, MD, PhD1,2, Sun Jun Kim, MD, PhD1,3

1Department of Pediatrics, Chonbuk National University Medical School, Jeonju, 2Department of Pediatrics, Pusan National University Children’s Hospital, Yangsan, 3Research Institute of Clinical Medicine, Chonbuk National University Medical School, Jeonju, Korea

Purpose: This study aimed to verify the safety of low-dose topiramate on language development in pediatric patients with migraine.

Methods: Thirty newly diagnosed pediatric patients with migraine who needed topiramate were enrolled and assessed twice with standard language tests, including the Test of Language Problem Solving Abilities (TOPs), Receptive and Expressive Vocabulary Test, Urimal Test of Articulation and Phonology, and computerized speech laboratory analysis. Data were collected before treatment, and topiramate as monotherapy was sustained for at least 3 months. The mean follow-up period was 4.3±2.7 months. The mean topiramate dosage was 0.9 mg/kg/day.

Results: The patient’s mean age was 144.1±42.3 months (male-to-female ratio, 9:21). The values of all the language parameters of the TOPs were not changed significantly after the topiramate treatment as follows: Determine cause, from 15.0±4.4 to 15.4±4.8 (P>0.05); making inference, from 11.5±4.5 to 12.3±4.0 (P>0.05); and total TOPs score, from 44.1±13.4 to 45.3±13.6 (P>0.05). The total mean length of utterance in words during the test decreased from 44.1±13.4 to 45.3±13.6 (P<0.05). The Receptive and Expressive Vocabulary Test results decreased from 97.7±22.1 to 96.3±19.9 months, and from 81.8±23.4 to 82.3±25.4 months, respectively (P>0.05). In the articulation and phonology validation in both groups, speech pitch and energy were not significant, and all the vowel test results showed no other significant values.

Conclusion: No significant difference was found in the language-speaking ability between the patients; however, the number of vocabularies used decreased. Therefore, topiramate should be used cautiously for children with migraine.

Key words: Child, Migraine, Prophylactic agents, Language, Topiramate

Introduction

Migraine is one of the most serious primary headaches in children and occurs in up to 10.6% of children aged 5–15 years1. Migraine attacks may have negative effects on every aspect of a child’s quality of life, including daily activities, interactions with peers, and family dynamics2,3. Therefore, many children with migraine who do not tolerate to conservative treatments or to nonsteroidal anti-inflammatory drugs are appropriate patients for prophylactic therapy.

Calcium channel blockers, β-blockers, serotonin antagonists, antidepressants, antihistamine mimetics, and antiepileptic drugs have been prescribed for migraine prophylaxis. Among these drugs, antiepileptic drugs, especially topiramate (TPM), are most frequently prescribed for children and adolescents. However, TPM should be used cautiously, particularly in pediatric patients, because TPM has several side effects: weight loss, hypohidrosis, paresthesia,
dizziness, kidney dysfunction, ataxia, acute myopia, and secondary angle closure glaucoma. TPM also can cause cognitive dysfunction, including language disturbances in patients with epilepsy when administered at the recommended dose. Several reports suggest that low dose TPM may lead to language disturbances in adult patients with migraine. However, there are no published reports investigating the effects of TPM on migraine in children. Therefore, this study aimed to verify the safety of low-dose TPM on language function in pediatric patients with migraine.

Materials and methods

1. Patients

Ninety-six pediatric patients diagnosed with migraine who needed TPM for migraine prevention because of the frequency more than 4 times per week were enrolled at the Department of Pediatrics of Chonbuk National University Hospital from May, 2011 to January, 2016. All patients received TPM monotherapy and were excluded when taking any medications which altered language function during follow-up. Brain magnetic resonance imaging and electroencephalography were examined to rule out secondary headaches and standard language tests were performed 2 times at minimum, at least 3 months apart. 30 patients were enrolled for this study after 66 patients were excluded. 58 patients excluded because of incomplete data and eight patients who needed other prophylactic medications for migraine were excluded. Bilingual patients were not included.

2. Methods

All patients were assessed at least twice using standard language tests: the Test of Language Problem Solving Abilities (TOPs), a Korean version of the Receptive & Expressive Vocabulary Test (K-REVT), Urimal Test of Articulation And Phonology for the articulation screening test, and the computerized speech lab 4500 (CSL Model 4500, Kay Elemetric 2004, Lincoln Park, NJ, USA) for speech analysis (voice onset time, total duration, vowel formant [F1, F2], pitch and energy).

The first language test was administered just prior to TPM treatment and the second test after at least 3 months of TPM therapy. We used the Korean versions of the language tests because all the patients exclusively spoke Korean. The average follow-up period was 4.3±2.7 months.

The starting dose of TPM was 25 mg/day at bedtime, and then was increased up to 100 mg/day or 1 mg/kg/day. The mean dosage was 0.9 mg/kg/day.

This study was performed with approval from the Institutional Review Board of Chonbuk National University Research Council (CUH 2014-07-008).

3. Language tests

1) Test of Language Problem Solving Abilities

TOPS is an evaluation tool that measures metalinguistic skills of transforming logical thinking to language in children between the ages of 5 and 12 years. The illustrations used in this test were developed by the Seoul Community Rehabilitation Center, Republic of Korea.

The TOPS is divided into 3 categories and contains a total of 17 illustrated materials. The first category consists of 18 questions about determining cause, including interrogative, “Why” questions (determining cause). The second category consists of 20 questions about problem solving, including “How” questions (making inference).

Finally, the third category consists of 12 questions about making predictions, including answers to questions such as “How do you know?” and “What happens?” (making predictions). Scores ranging from 0 to 2 were assigned depending on responses to each category, with a top score of 100. Answers were recorded and documented immediately after the tests were completed. Scores were defined as raw scores, mean scores, and total scores for each category. The length of articulation for each answer was compared using the mean length of utterance in words (MLU-w), which is defined as the mean score of the length of articulation obtained by adding all the words in the answer divided by the number of sentences included in the answer.

2) Korean version of the Receptive & Expressive Vocabulary Test

The Receptive & Expressive Vocabulary Test (REVT) is a standardized test that is approved for evaluation of receptive and expressive vocabulary development and is applicable to children from 2 years old to adult. Raw scores were calculated based on basal and ceiling results, and equivalent ages were also measured.

3) Urimal test of articulation and phonology

The Urimal test of articulation and phonology (U-TAP; Urimal means Korean language) is a test designed for individuals with abnormal articulation that have a systematic approach in solving articulation problems by examining their pronunciation in a single vocabulary or in a sentence. The test, designed for patients from 2 to 12 years old, presents a certain picture to the children and leads them to make a sentence which includes a targeted phoneme. Accuracy is calculated by dividing the number of incorrect phonems by the total number of phonems and is expressed as percent correct.

4) CSL analysis

The computerized speech laboratory (CSL) is an acoustic analysis system with robust hardware for data acquisition, complemented by a versatile suite of software available for speech analysis, teach-
ng, research, voice measurement, clinical feedback, acoustic phonetics, and forensic work. The equipment allows for the simultaneous capture of microphonic and laryngographic signals. The individual is asked (after an adequate training) to emit a sustained /a/, /e/, /i/, /o/, /u/ and a short sentence. The standard deviations of the intensity and frequency of the sentence (expressed as the percentage of to the mean value) were obtained.

4. Statistical analysis
Statistical significance was determined analyzed using IBM SPSS version 22.0 for Windows (SPSS Inc., Chicago, IL, USA). Paired t tests were used to compare differences before and after TPM treatment. All values are expressed as mean±standard deviation. The value $P<0.05$ was considered significant.

Results
The mean age of patients was 144.1±42.3 months (male:female ratio=1:2.3). Patients did not change drugs, and completed all follow-up language tests during the study period.

Twenty patients responded well to the treatment, and patients' migraine was reduced after taking TPM. There were 5 patients who showed no significant differences in in headache frequency or headache-related disability. In 5 patients, the migraine was aggravated. Among of these 5 patients, 3 patients had a medication change after the second language test was completed.

1. Results of the TOPS
The language parameters of TOPs were changed after TPM treatment; however, it was not statistically significant. The highest score in the “Determine cause” category was 22. There was no significant difference between baseline (15.0±4.4) and TPM treatment scores (15.4±4.8, $P>0.05$) (Table 1). The highest score in the “making inference” category was 30. The mean score at baseline was 17.7±5.6 and 17.6±6.6 after TPM treatment; this difference was also not significant ($P>0.05$) (Table 1).

The highest score in the “Predicting” category was 20. The mean score of 11.5±4.5 was obtained for pediatric migraine patients before TPM treatment, which increased to 12.3±4.0 after taking TPM. Moreover, this value was not significant (Table 1) ($P>0.05$).

Total score of TOPs which differences before and after TPM monotherapy was not significant (Table 1) ($P>0.05$). Of a maximum score of 100, the mean score of patients before taking TPM was 44.1±13.5, which increased to 45.3±13.6 after taking TPM.

2. MLU-w in TOPS
The total mean length of utterance in words (MLU-w) during the test decreased from 5.5±2.0 to 4.9±1.5 after TPM treatment (Table 2) ($P<0.05$).

The difference in MLU-w for the “determine cause” category of questions before and after TPM treatment was significant, decreasing from 5.5±1.7 to 4.3±1.3 (Table 2) ($P<0.05$).

With respect to “making inference” the mean MLU-w score decreased 6.2±2.1 to 4.6±1.5 ($P<0.05$) after taking TPM. However, the “predicting” category of the mean MLU-w score decreased from 5.5±2.3 to 4.3±1.8 after TPM treatment; however, it was not significant (Table 2) ($P>0.05$).

3. Results of the REVT
REVT did not change significantly. In the Receptive Vocabulary Test, the mean score of 97.8±22.1 was obtained for patients with pediatric migraine before TPM treatment, which decreased to 96.3±20.0 after taking TPM. In addition, Expressive Vocabulary Test was 81.8±23.4 to 82.3±25.4 months. In the control group, the Receptive Vocabulary Test was 112.5±17.9 and Expressive Vocabulary Test was 94.1±9.3 ($P<0.05$).

4. Result of U-TAP
U-TAP has not been shown any specific change. When we compare the groups premedication and postmedication, there was no damage found in articulation and phonology validation in both groups and control group which have 100%.

The mean score of pitch test increased from 209.8±27.9 to 211.3±34.6 after TPM treatment ($P>0.05$). In the energy test, the mean score of 58.6±7.4 was obtained for pediatric patients with migraine before TPM treatment, which increased to 59.5±6.6 after taking TPM. For parameter pitch and energy, there was no significant influence on the data from the measuring between the groups. There was no corresponding significant influence of medication for both

| Variable             | Pre TPM   | Post TPM  |
|---------------------|-----------|-----------|
| Determine cause     | 15.0±4.4  | 15.4±4.8  |
| Making inference    | 17.7±5.6  | 17.6±6.6  |
| Predicting          | 11.5±4.5  | 12.3±4.0  |
| Total               | 44.1±13.4 | 45.3±13.6 |

Values are presented as mean±standard deviation. Pre TPM, before topiramate treatment; Post TPM, during topiramate treatment.

| Variable             | Pre TPM   | Post TPM  |
|---------------------|-----------|-----------|
| Determine cause     | 5.5±1.7   | 4.3±1.3*  |
| Making inference    | 6.2±2.1   | 4.6±1.5*  |
| Predicting          | 5.5±2.3   | 4.3±1.8   |
| Total               | 5.5±2.0   | 4.9±1.5*  |

Values are presented as mean±standard deviation. Pre TPM, before topiramate treatment; Post TPM, during topiramate treatment. *$P<0.05$.
Table 3. The results of the computer science laboratory analysis for bowel sound

| Variable | Pre TPM | Post TPM |
|----------|---------|----------|
| Pitch    | 209.82±27.9 | 211.3±34.6 |
| Energy   | 58.57±7.4  | 59.5±6.6  |
| Vowel sound |        |          |
| /a/ F1   | 1,032.2±237.6 | 1,074.9±167.8 |
| /a/ F2   | 1,944.6±452.6 | 2,020.1±522.9 |
| /i/ F1   | 399.6±53.7  | 323.6±69.7 |
| /i/ F2   | 2,931.5±243.5 | 2,837.6±249.2 |
| /u/ F1   | 396.4±103.0 | 396.9±82.5 |
| /u/ F2   | 1,652.0±745.2 | 1,471.0±579.4 |
| /e/ F1   | 650.6±152.2 | 590.3±137.4 |
| /e/ F2   | 2,376.3±289.4 | 2,444.1±185.1 |
| /o/ F1   | 410.4±72.3  | 409.80±72.1 |
| /o/ F2   | 1,137.7±344.9 | 1,161.80±484.9 |

Values are presented as mean±standard deviation.

Pre TPM, before topiramate treatment; Post TPM, during topiramate treatment; F1, formants 1; F2, formants 2.

Discussion

Although TPM was initially developed for the treatment of epilepsy, it is an effective migraine preventive therapy in adults, as demonstrated in several studies\(^{16,17}\). The doses of TPM required to treat migraine are lower than those needed to treat epilepsy, resulting in a lower prevalence of adverse effects\(^ {18}\). Treatment options for pediatric migraine are particularly limited, and there are few migraine preventive agents approved for use in children\(^ {19,20}\). Thus, preventive pharmacologic treatments for migraine in children need to be based on efficacy and safety. Precisely how TPM prevents migraine is unclear; however, generally, it appears to reduce the genetically-derived headache that provokes migraine attacks in susceptible individuals.

Fallah et al.\(^ {21}\) showed TPM as a safe and effective drug for pediatric migraine prophylaxis, which reduces monthly frequency, severity, duration, and disability of migraine in children. Other studies have shown that TPM at 100 mg/day is effective in the prevention of migraine headaches and in reducing the severity of the attack\(^ {22-24}\). Similarly, the present study showed that TPM is effective in the reducing migraine. In contrast, several studies have reported language impairments such as deterioration of verbal expression, verbal learning, work memory, and verbal fluency with TPM treatment\(^ {25-28}\). In our study, we analyzed the effects of TPM on language development using a set of specific language evaluation tools. Pediatric patients with migraine with no history of anticonvulsant medication were evaluated on the basis of language characteristics before and after TPM medication using TOPs, MLU-w, REVT, U-TAP, and CSL prospective analysis throughout the study.

The TOPs was used to examine problem-solving ability, which refers to the ability to comprehend the causes of events, speculate on conditions, and solve problems\(^ {13}\). There was no significant difference in language problem-solving skills before and after TPM treatment. The mean “determine cause” score declined in 13 of 30 patients (43.3%) after TPM, the mean “making inference” score declined in 16 of 30 patients (53.3%), and the mean “predicting” score was reduced in 14 of 30 patients (46.6%). In the MLU-w portion of the TOPs, the mean “determine cause” score decreased from 5.5 to 4.3, the mean “making inference” score decreased from 6.2 to 4.6, and the mean “predicting” score decreased from 5.5 to 4.3 following TPM treatment. Similarly, the total problem-solving MLU-w score decreased from 5.5 to 4.9 after TPM treatment. These results show that TPM treatment may cause vocabulary function impairment in problem solving and deterioration of speaking sufficient sentences. After TPM medication, the answers of the examinees appeared to become more ambiguous, were phrased in shorter sentences, and were delayed because of difficulties in word choice selection. Furthermore, improper grammar was used in some cases. This suggests that attention is required when TPM is used in pediatric migraine patients.

The REVT was used as a tool for comparative analysis of receptive vocabulary development skills, which encompasses the ability to see, hear, and understand linguistic stimuli\(^ {13}\). Receptive vocabulary test and expressive vocabulary test were compared before and after TPM monotherapy in our study. Although 12 of 30 patients’ score was decreased in the receptive vocabulary test and 8 of 30 patients’ score was decreased in the expressive vocabulary test, REVT was not significant.

In addition, the results of U-TAP remained unchanged. In CSL analysis, all correlations were not significant.

This study has several limitations. First, this study lacked language evaluation tools. Second, it was conducted at a single center with a smaller subject group. Finally, larger studies are required to evaluate the long-term efficacy, optimal dose, length of treatment, and long-term effects of TPM. Future studies could be considered with positive effects of language development after reductions in migraine headache.

In conclusion, our results show that TPM is effective in the prevention of migraine headache and in reducing the severity of the attack. Furthermore, we found no difference with the ability of
language problems between patients; however, still there is deterioration in the number of the vocabularies they use. Therefore, it is recommended to use TPM while considering the side effects of language in pediatric patients with migraine even at low doses.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

References

1. Hershey AD. Migraine. In: Kliegman RM, Stanton BF, St. Geme JW III, Schor NF, Behrman RE, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia: Elsevier/Saunders, 2011:2040-5.
2. Split W, Neuman W. Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache 1999;39: 494-501.
3. Lee LH, Olness KN. Clinical and demographic characteristics of migraine in urban children. Headache 1997;37:269-76.
4. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43.
5. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46:1684-90.
6. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46:1678-83.
7. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24.
8. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8.
9. Fritz N, Giogou S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6:373-81.
10. Tang Y, Xia W, Yu X, Zhou B, Wu X, Lui S, et al. Altered cerebral activity associated with topiramate and its withdrawal in patients with epilepsy with language impairment: an fMRI study using the verb generation task. Epilepsy Behav 2016;59:98-104.
11. Coppola F, Rossi C, Mancini ML, Corbelli I, Nardi K, Sarchielli P, et al. Language disturbances as a side effect of prophylactic treatment of migraine. Headache 2008;48:86-94.
12. Bae SY, Lim SS, Lee JH. Test of problem solving. Seoul: Seoul Community Rehabilitation Center, 2005.
13. Kim SJ, Kim MY, Choi YM, Song MK. Effects of topiramate on language functions in newly diagnosed pediatric epileptic patients. Pediatr Neurol 2014;51:324-9.
14. Kim YT, Hong GH, Kim KH. Content and reliability analyses of the receptive and expressive vocabulary test (REV). Commun Sci Discord 2009;14:34-45.
15. Kim YJ, Shin MJ. Urimal Test of Articulation and Phonology (U-TAP). Seoul: Hakjisa, 2004.
16. Silberstein SD. Topiramate in migraine prevention. Headache 2005;45 Suppl 1:S57-65.
17. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41:968-75.
18. Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005;45 Suppl 1:S66-73.
19. Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hultihan J, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:1304-12.
20. Lakshmi CV, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol 2007;22:829-35.
21. Fallah R, Akhavan Karbasi S, Shajari A, Fromandi M. The efficacy and safety of topiramate for prophylaxis of migraine in children. Iran J Child Neurol 2013;7:7-11.
22. Diamond M, Dahlöf C, Papadopoulos G, Neto W, Wu SC. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005;45:1023-30.
23. Bussone G, Pefi J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a randomized blinded crossover study. Headache 2001;41:968-75.
24. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642-8.
25. Marino SE, Pakhomov SV, Han S, Anderson KL, Ding M, Eberly LE, et al. The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory. Epilepsy Behav 2012;24:365-72.
26. Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol 2013;111:707-18.
27. Baeta E, Santana I, Castro G, Gonçalves S, Gonçalves T, Carro I, et al. Cognitive effects of therapy with topiramate in patients with refractory partial epilepsy. Rev Neurol 2002;34:737-41.
28. de Araujo Filho GM, Pascalichio TF, Lin K, Sousa PS, Yacubian EM. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav 2006;8:606-9.

https://doi.org/10.3345/kjp.2017.60.7.227